Acrivon Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Acrivon Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.5 times its market value (net cash). Higher than 93% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-30.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 64% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-54.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 75% of Healthcare companies in United States.
Cash Cushion Ratio
1.5× cashCash, after subtracting all debt, is 1.5 times its market value (net cash).
Higher than 93% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Acrivon Therapeutics, Inc. made a loss over the last year. Acrivon Therapeutics, Inc. owes $0.13 for every $1 it owns. Acrivon Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAcrivon Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.87The share price is 0.87 times Acrivon Therapeutics, Inc.'s book value per share, lower than 82% of Healthcare companies in United States.
Market cap
$75 MThe total market value of all of Acrivon Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$87 MWhat Acrivon Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.02Net worth divided by the number of shares. The share price of $1.76 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-64.6%Acrivon Therapeutics, Inc. lost 64.6% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
Owes vs Owns
0.13×Acrivon Therapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NoneAcrivon Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossAcrivon Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashAcrivon Therapeutics, Inc. held $116 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Acrivon Therapeutics, Inc.: $75 M ÷ $87 M (30 Jun 2026) = 0.9.
What is Acrivon Therapeutics, Inc.'s return on equity?
Acrivon Therapeutics, Inc. lost 64.6% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
How much does Acrivon Therapeutics, Inc. owe compared with what it owns?
Acrivon Therapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does Acrivon Therapeutics, Inc. pay a dividend?
No. Acrivon Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.